Holen Sie sich die Stockscreener-App
35.41
2.02%
0.70
Handel nachbörslich:
35.03
-0.38
-1.07%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TEVA?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$34.71
Offen:
$34.35
24-Stunden-Volumen:
8.77M
Relative Volume:
1.43
Marktkapitalisierung:
$41.23B
Einnahmen:
$17.53B
Nettoeinkommen (Verlust:
$1.58B
KGV:
26.31
EPS:
1.3457
Netto-Cashflow:
$444.18M
1W Leistung:
+13.57%
1M Leistung:
+4.52%
6M Leistung:
+3.90%
1J Leistung:
+110.40%
1-Tages-Spanne:
$34.27
$35.87
1-Wochen-Bereich:
$30.77
$35.87
52-Wochen-Spanne:
$14.99
$37.34
Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Company Profile
Firmenname
Teva Pharmaceutical Industries Ltd Adr
Sektor
Telefon
972 (3) 914-8213
Adresse
TEVA PHARMACEUTICAL INDUSTRIES LIMITED, TEL AVIV
Compare TEVA vs TAK, HLN, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.41 | 36.19B | 17.53B | 1.58B | 444.18M | 1.3457 |
TAK
Takeda Pharmaceutical Co Adr
|
17.25 | 55.69B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
10.11 | 43.77B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
76.03 | 32.25B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
525.82 | 26.29B | 3.17B | 1.29B | 1.01B | 27.09 |
Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-12-05 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-06-06 | Eingeleitet | Goldman | Buy |
| 2025-05-28 | Eingeleitet | Truist | Buy |
| 2025-05-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-07-10 | Hochstufung | Argus | Hold → Buy |
| 2024-03-08 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2024-02-12 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-01-23 | Hochstufung | Jefferies | Hold → Buy |
| 2024-01-03 | Hochstufung | Piper Sandler | Underweight → Neutral |
| 2023-12-18 | Eingeleitet | HSBC Securities | Buy |
| 2023-11-27 | Hochstufung | UBS | Neutral → Buy |
| 2023-07-06 | Hochstufung | UBS | Sell → Neutral |
| 2023-05-25 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2023-05-18 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-01-19 | Herabstufung | Jefferies | Buy → Hold |
| 2022-11-14 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-11-04 | Herabstufung | UBS | Neutral → Sell |
| 2022-10-21 | Fortgesetzt | Jefferies | Buy |
| 2022-08-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-06-14 | Fortgesetzt | UBS | Neutral |
| 2022-05-17 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-05-04 | Herabstufung | Piper Sandler | Neutral → Underweight |
| 2022-04-05 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2022-03-25 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2022-01-27 | Herabstufung | Argus | Buy → Hold |
| 2021-10-28 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2021-05-04 | Herabstufung | UBS | Buy → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2020-11-25 | Eingeleitet | Oppenheimer | Perform |
| 2020-08-06 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2020-07-27 | Fortgesetzt | Goldman | Neutral |
| 2020-06-01 | Hochstufung | SunTrust | Hold → Buy |
| 2020-04-24 | Fortgesetzt | Citigroup | Neutral |
| 2020-04-06 | Hochstufung | UBS | Neutral → Buy |
| 2020-02-24 | Herabstufung | Edward Jones | Hold → Sell |
| 2019-11-12 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2019-10-17 | Hochstufung | Gabelli & Co | Hold → Buy |
| 2019-08-07 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-07-19 | Eingeleitet | Wolfe Research | Peer Perform |
| 2019-07-15 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2019-07-10 | Fortgesetzt | Credit Suisse | Neutral |
| 2019-07-05 | Hochstufung | Argus | Hold → Buy |
| 2019-06-11 | Eingeleitet | Barclays | Underweight |
| 2019-06-03 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-05-30 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2019-05-28 | Herabstufung | UBS | Buy → Neutral |
| 2019-03-20 | Eingeleitet | SunTrust | Hold |
| 2019-03-07 | Fortgesetzt | UBS | Buy |
Alle ansehen
Teva Pharmaceutical Industries Ltd Adr Aktie (TEVA) Neueste Nachrichten
Daily Brief Health Care: Apnimed, Chugai Pharmaceutical, Equifax Inc, Royalty Pharma , Startline, Surgery Partners, Teva Pharmaceutical Sp Adr, Thermo Fisher Scientific Inc and more - Smartkarma
Teva Pharmaceutical Industries Limited Sponsored ADR Revenue Breakdown – BX:TEV - TradingView
Does Teva Pharmaceutical Industries (NYSE:TEVA) Still Look Undervalued After A 260% Run? - Sahm
Teva Pharmaceutical Industries Limited (TEVA) stock price, news, quote and history - Yahoo Finance UK
Teva Pharmaceutical Industries Limited (TEVA) Stock Price, News, Quote & History - Yahoo! Finance Canada
ETFs Investing in Teva Pharmaceutical Industries Limited Sponsored ADR Stocks - TradingView
What Teva Pharmaceutical Industries (TEVA)'s TEV‑408 Vitiligo Data and Funding Deal Means For Shareholders - Sahm
MINT,TEVA Volatility & Greeks - Finviz
Teva Pharmaceutical Industries (TEVA) Advances TEV 408, Is The Stock Still Cheap? - Sahm
Teva (TEVA) Stock Looks Reasonable Even With A 48% Gap - Sahm
Teva (TEVA) Advances TEV 408 Into Phase 2b For Vitiligo After Early Progress - Sahm
Novartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026? - The Motley Fool
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis - Sahm
Teva Reports Early Skin Repigmentation Data, Sets Stage For Next Trial - Sahm
TEVA Stock Price | Analyst Target 42.38 & Strong Buy Consensus - eToro
Teva stock leans on its generic drug base. - Ad-hoc-news.de
883035 Forecast — Price Target — Prediction for 2027 - TradingView
TEVATeva- Pharmaceutical Industries Ltd ADR Latest SEC Filings - Finviz
How Teva’s Ecopipam NDA for Pediatric Tourette Syndrome (TEVA) Has Changed Its Investment Story - Sahm
TEVA Stock Price, Quote & Chart - ChartMill
Enterprise value to revenue forward of Teva Pharmaceutical Industries Limited Sponsored ADR – BX:TEV - TradingView
Price to earnings forward of Teva Pharmaceutical Industries Limited Sponsored ADR – BX:TEV - TradingView
TEV Forecast — Price Target — Prediction for 2027 - TradingView
TEVA Forecast — Price Target — Prediction for 2027 - TradingView
TEVA/N Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to revenue forward of Teva Pharmaceutical Industries Limited Sponsored ADR – FWB:TEV - TradingView
Price to earnings forward of Teva Pharmaceutical Industries Limited Sponsored ADR – FWB:TEV - TradingView
Enterprise value to EBITDA forward of Teva Pharmaceutical Industries Limited Sponsored ADR – FWB:TEV - TradingView
Teva Pharmaceutical Industries Ltd Unsponsored Brazilian Depositary Receipt Repr 0.5 ADR - TradingView
Teva Pharmaceutical Industries Limited Sponsored ADR - TradingView
TEVA News | TEVA PHARMACEUTICAL-SP ADR (NYSE:TEVA) - ChartMill
Teva's Shift Beyond Generics Puts Focus on Branded Drug Growth - TradingView
How Teva’s Ecopipam Tourette NDA and AUSTEDO Data Will Impact Teva Pharmaceutical Industries (TEVA) Investors - Sahm
Teva Pharmaceutical Industries (TEVA) Stock Could Be 23.7% Undervalued After Recent Pullback - Sahm
Teva Seeks FDA Nod for Ecopipam in Pediatric Tourette Syndrome - Yahoo Finance
Teva submits new drug application for pediatric Tourette treatment By Investing.com - Investing.com Canada
FOCUS-US progesterone supplies tighten as menopause treatment demand grows - Sahm
Teva Extends Neuroscience Focus With Emalex Deal And Valuation Upside Potential - Sahm
Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy - Sahm
symbol__ Stock Quote Price and Forecast - CNN
ALVO Stock Gains 19% on FDA Resubmission of Biosimilar BLAs - TradingView
How Investors May Respond To Teva (TEVA) Pivoting From Generics Toward Higher-Margin Branded Therapies - Sahm
Teva stock hits 52-week high at $32.02 By Investing.com - Investing.com Nigeria
Assessing Teva (NYSE:TEVA) Valuation After New IMPACT-TD Registry Findings On Tardive Dyskinesia - Sahm
TEVA PHARMACEUTICAL-SP ADR (NYSE:TEVA) Flags Technical Breakout Setup with Top Ratings - ChartMill
Teva- Pharmaceutical Industries Ltd.ADR (TEVA) News, Articles, Events & Latest Updates - Stocktwits
Updating Moat and Valuation for Teva to Reflect Improved Outlook - Morningstar
Teva: Upgrading Moat and Raising Valuation on Portfolio Improvements and Deep Pipeline - Morningstar
Finanzdaten der Teva Pharmaceutical Industries Ltd Adr-Aktie (TEVA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.65%
0.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):